To Generate Microbial Hypotheses Putatively Responsible for the Onset of Liver Fibrosis Clinical Trial
— ROLIVEROfficial title:
ROLIVER - Prospective Cohort for the Identification of Liver Microbiota
| NCT number | NCT03511573 |
| Other study ID # | TirguMECCH |
| Secondary ID | |
| Status | Completed |
| Phase | |
| First received | |
| Last updated | |
| Start date | January 1, 2014 |
| Est. completion date | January 31, 2017 |
| Verified date | April 2018 |
| Source | Tîrgu Mure? Emergency Clinical County Hospital, Romania |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Observational |
The existence of an adipose tissue microbiota causally involved in the triggering of a low grade inflammation could resemble what observed in liver fibrosis. To generate microbial hypotheses putatively responsible for the onset of liver fibrosis we sequenced the 16SrDNA gene from liver biopsies from 36 obese patients (ROLIVER cohort) and describe an original mathematical approach to decipher signatures of early stage of liver fibrosis F0, F1, F2.
| Status | Completed |
| Enrollment | 36 |
| Est. completion date | January 31, 2017 |
| Est. primary completion date | December 31, 2016 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | All |
| Age group | N/A and older |
| Eligibility |
Inclusion Criteria: - bariatric patients - morbid obesity patients Exclusion Criteria: - serious chronic associated illness (heart failure, cirrhosis, panhypopituitarism or autoimmune diseases), consumption of alcohol (> 20 g ethanol intake per day), related use of medication (use of laxatives, fiber supplements or probiotics in the previous 6 weeks), inflammatory disorders and use of immunomodulatory drugs. Other exclusion criteria were: history of bariatric surgery, use of anti-obesity drugs in the previous 3 months, recent (last 2 months) or on-going antibiotic use, excessive use of vitamin D supplementation; active or recent (last 3 months), participation in a weight loss program or weight change of 3 kg during the past 3 months, pregnant or planning pregnancy within 6 months or breastfeeding women, drug abuse, and other reasons identified by the Investigator. |
| Country | Name | City | State |
|---|---|---|---|
| n/a | |||
| Lead Sponsor | Collaborator |
|---|---|
| Tîrgu Mure? Emergency Clinical County Hospital, Romania |
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | a positive or a negative linear regression between 16SrDNA sequences and liver fibrosis scores | the frequency of some 16SrDNA in the liver should be positively or negatively correlated with the score of liver fibrosis | 36 months |